Literature DB >> 35486214

Circulating cell-free mtDNA release is associated with the activation of cGAS-STING pathway and inflammation in mitochondrial diseases.

Xutong Zhao1, Meng Yu1, Yawen Zhao1, Yiming Zheng1, Lingchao Meng1, Kang Du1, Zhiying Xie1, He Lv1, Wei Zhang1, Jing Liu1, Qingqing Wang1, Yun Yuan1, Zhaoxia Wang2,3, Jianwen Deng4,5.   

Abstract

BACKGROUND: There is increasing evidence for the role of inflammation in the pathogenesis of mitochondrial diseases (MDs). However, the mechanisms underlying mutation-induced inflammation in MD remain elusive. Our previous study suggested that mitophagy is impaired in the skeletal muscle of those with MD, likely causing mitochondrial DNA (mtDNA) release and thereby triggering inflammation. We here aimed to decipher the role of the cGAS-STING pathway in inflammatory process in MDs.
METHODS: We investigated the levels of circulating cell-free mtDNA (ccf-mtDNA) in the serum of 104 patients with MDs. Immunofluorescence was performed in skeletal muscles in MDs and control. Biochemical analysis of muscle biopsies was conducted with western blot to detect cGAS, STING, TBK1, IRF3 and phosphorylated IRF3 (p-IRF3). RT-qPCR was performed to detect the downstream genes of type I interferon in skeletal muscles. Furthermore, a protein microarray was used to examine the cytokine levels in the serum of patients with MDs.
RESULTS: We found that ccf-mtDNA levels were significantly increased in those with MDs compared to the controls. Consistently, the immunofluorescent results showed that cytosolic dsDNA levels were increased in the muscle samples of MD patients. Biochemical analysis of muscle biopsies showed that cGAS, IRF3, and TBK1 protein levels were significantly increased in those with MDs, indicating that there was activation of the cGAS-STING pathway. RT-qPCR showed that downstream genes of type I interferon were upregulated in muscle samples of MDs. Protein microarray results showed that a total of six cytokines associated with the cGAS-STING pathway were significantly increased in MD patients (fold change > 1.2, p value < 0.05).
CONCLUSIONS: These findings suggest that increases in ccf-mtDNA levels is associated with the activation of the cGAS-STING pathway, thereby triggering inflammation in MDs.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Ccf-mtDNA; Inflammation; Mitochondrial diseases; cGAS-STING pathway

Mesh:

Substances:

Year:  2022        PMID: 35486214     DOI: 10.1007/s00415-022-11146-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   6.682


  36 in total

1.  Mitochondrial complex I activity suppresses inflammation and enhances bone resorption by shifting macrophage-osteoclast polarization.

Authors:  Zixue Jin; Wei Wei; Marie Yang; Yang Du; Yihong Wan
Journal:  Cell Metab       Date:  2014-08-14       Impact factor: 27.287

Review 2.  MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options.

Authors:  Ayman W El-Hattab; Adekunle M Adesina; Jeremy Jones; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2015-06-15       Impact factor: 4.797

3.  RNA-seq profiling, and impaired autophagic process in skeletal muscle of MELAS.

Authors:  Jianwen Deng; Yuanyuan Lu; Zhiying Xie; Jing Liu; Yun Yuan; Zhaoxia Wang
Journal:  Biochem Biophys Res Commun       Date:  2019-12-10       Impact factor: 3.575

Review 4.  Recent Advances in Mitochondrial Disease.

Authors:  Lyndsey Craven; Charlotte L Alston; Robert W Taylor; Doug M Turnbull
Journal:  Annu Rev Genomics Hum Genet       Date:  2017-04-17       Impact factor: 8.929

5.  Inhibition of the ER stress IRE1α inflammatory pathway protects against cell death in mitochondrial complex I mutant cells.

Authors:  Meghan S Soustek; Eduardo Balsa; Joeva J Barrow; Mark Jedrychowski; Rutger Vogel; Steve P Gygi; Pere Puigserver
Journal:  Cell Death Dis       Date:  2018-05-31       Impact factor: 8.469

Review 6.  ccf-mtDNA as a Potential Link Between the Brain and Immune System in Neuro-Immunological Disorders.

Authors:  Stefano Gambardella; Fiona Limanaqi; Rosangela Ferese; Francesca Biagioni; Rosa Campopiano; Diego Centonze; Francesco Fornai
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

7.  Tetracyclines promote survival and fitness in mitochondrial disease models.

Authors:  Elizabeth A Perry; Christopher F Bennett; Chi Luo; Eduardo Balsa; Mark Jedrychowski; Katherine E O'Malley; Pedro Latorre-Muro; Richard Porter Ladley; Kamar Reda; Peter M Wright; Steven P Gygi; Andrew G Myers; Pere Puigserver
Journal:  Nat Metab       Date:  2021-01-18

8.  Defective NADPH production in mitochondrial disease complex I causes inflammation and cell death.

Authors:  Eduardo Balsa; Elizabeth A Perry; Christopher F Bennett; Mark Jedrychowski; Steven P Gygi; John G Doench; Pere Puigserver
Journal:  Nat Commun       Date:  2020-06-01       Impact factor: 14.919

9.  Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism.

Authors:  Max Borsche; Inke R König; Sylvie Delcambre; Simona Petrucci; Alexander Balck; Norbert Brüggemann; Alexander Zimprich; Kobi Wasner; Sandro L Pereira; Micol Avenali; Christian Deuschle; Katja Badanjak; Jenny Ghelfi; Thomas Gasser; Meike Kasten; Philip Rosenstiel; Katja Lohmann; Kathrin Brockmann; Enza Maria Valente; Richard J Youle; Anne Grünewald; Christine Klein
Journal:  Brain       Date:  2020-10-01       Impact factor: 13.501

10.  Circulating Cell-Free Mitochondrial DNA in Cerebrospinal Fluid as a Biomarker for Mitochondrial Diseases.

Authors:  Selena Trifunov; Abraham J Paredes-Fuentes; Carmen Badosa; Anna Codina; Julio Montoya; Eduardo Ruiz-Pesini; Cristina Jou; Glòria Garrabou; Josep M Grau-Junyent; Dèlia Yubero; Raquel Montero; Jordi Muchart; Juan D Ortigoza-Escobar; Maria M O'Callaghan; Andrés Nascimento; Albert Català; Àngels Garcia-Cazorla; Cecilia Jimenez-Mallebrera; Rafael Artuch
Journal:  Clin Chem       Date:  2021-08-05       Impact factor: 8.327

View more
  2 in total

1.  Simplified regimen of combined low-dose rituximab for autoimmune encephalitis with neuronal surface antibodies.

Authors:  Ying Du; Chao Zhao; Juntong Liu; Chuan Li; Qi Yan; Lin Li; Yunfeng Hao; Dan Yao; Huaxing Si; Yingjun Zhao; Wei Zhang
Journal:  J Neuroinflammation       Date:  2022-10-22       Impact factor: 9.587

Review 2.  Mitochondrial VDAC1: A Potential Therapeutic Target of Inflammation-Related Diseases and Clinical Opportunities.

Authors:  Hang Hu; Linlin Guo; Jay Overholser; Xing Wang
Journal:  Cells       Date:  2022-10-10       Impact factor: 7.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.